Onkos Surgical has announced the enrollment of the first patient in its Post-Market Surveillance Study of the ELEOS Limb Salvage System with NanoCept Antibacterial Implant Technology.
This first and only orthopaedic antibacterial coating technology available on the U.S. market offers a proactive approach against intraoperative bacterial contamination, a crucial advancement in the field of orthopaedic implants, according to a news release.
“The enrollment of the first patient in this study marks another major milestone in the NanoCept journey, and reinforces our firm commitment to individuals with complex orthopaedic conditions,” said Patrick Treacy, Onkos Surgical CEO and co-founder. “We look forward to executing this study, as part of our agreement with FDA in conjunction with our original De Novo authorization, and continuing to bring this novel technology to surgeons and patients in need. We are very excited about the potential to help patients with this transformational technology, the likes of which we have not seen in 30 years.”
Over 100 patients will be enrolled in a multicenter study across the United States. In preclinical testing supporting the original De Novo market authorization, NanoCept demonstrated up to a 99.999% (5-log reduction) kill rate of bacteria that are commonly found in the operating room environment.
“The musculoskeletal oncology surgeons at The James have a long history of providing innovative options for our patients with malignant bone tumors that require limb reconstruction for maintenance of function as part of their cancer treatment,” said Joel Mayerson, MD, orthopedic oncologist, director of the sarcoma program and chief of musculoskeletal oncology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCC–James). “This multi-institutional national post-market surveillance study will help define the future of how we can improve outcomes for patients while working toward a cancer-free world.”
“As a national referral center for musculoskeletal oncology and complex limb reconstruction, Ohio State’s Department of Orthopedics is committed to advancing limb salvage and reconstructive surgery through clinical innovation and rigorous research,” said Carl Quinion, MD, the study’s principal investigator for the site and an orthopedic surgeon at the OSUCCC-James. “Bacterial contamination remains a major risk in this patient population, and preventing and managing prosthetic joint complications is a central focus of our clinical and research efforts. This multi-center study allows us to systematically evaluate new approaches within complex reconstruction to better inform future care and improve outcomes for our patients.”
“Since its first use in December 2024, the orthopaedic market has shown steadily increasing demand for the NanoCept technology. Momentum for new products with NanoCept technology is growing as demonstrated by FDA issuing 510(k) clearance for the ELEOS Proximal Tibia with NanoCept Antibacterial Technology on October 21, 2025. To meet the increasing demand, Onkos opened its NanoCept Innovation Center in Bridgewater, NJ on December 9, 2025, to expand production capacity for this exciting technology,” the release adds.
